# Petitioner Liquidia Technologies, Inc.

# Oral Argument Demonstratives

May 13, 2022

Liquidia Technologies, Inc. v. United Therapeutics Corp., IPR2021-00406

U.S. Patent No. 10,716,793

Petitioner's Ex. 1134 - IPR2021-00406

# Person of Ordinary Skill in the Art

TIVE EXHIBIT – NOT EVIDENCE

# Person of Ordinary Skill in the Art:

o Dispute that Dr. Hill, Dr. Gonda, Dr. Waxman, and Dr. McConville are POSAs

### Liquidia

**Proposed Definition** 

#### <u>Nethod of treating pulmonary hypertension</u>:

nedical degree with a specialty in pulmonology or cardiology, plus at east two years of experience treating patients with pulmonary ypertension as an attending, including with inhaled therapies, or quivalent degree or experience.

# <u>nhaled formulations used in the method to treat pulmonary</u> ypertension:

h.D. in pharmaceutical science or a related discipline like chemistry or nedicinal chemistry, plus two years of experience in pharmaceutical ormulations, including inhaled products, or equivalent (e.g., an M.S. in he same fields, plus 5 years of experience).

#### **UTC**

### **Proposed Definition**

M.D. or a graduate degree (Masters or Ph.D.) in a field relating to drug development and at least two years practical experience in either (i) the investigation or treatment of pulmonary hypertension; or (ii) in the development of potential drug candidates, specifically in the delivery of drugs by inhalation.

Pet. 13-14; POR 7-8

# Grounds and Claims

TIVE EXHIBIT – NOT EVIDENCE

## Grounds for Consideration

## Ground 1 (Claims 1-8): '212 Patent, Voswinckel JESC, Voswinckel JAHA

- '212 Patent = treatment of pulmonary hypertension with inhaled treprostinil, inhalation devices, solution and powder formulations
- Voswinckel JESC = therapeutically effective single event dose of 15-90μg
- Voswinckel JAHA = 3 breaths

## Ground 2 (Claims 1-8): '212 Patent, Voswinckel JESC

- '212 Patent = treatment of pulmonary hypertension with inhaled treprostinil, inhalation devices, solution and powder formulations
- Voswinckel JESC = therapeutically effective single event dose of 15-90µg and routine optimization to achieve 3 breaths

## All are UTC publications.

Pet. 30-50; Reply 1-23; EX1006; EX1007, 7; EX1008

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

### **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

#### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

